

BIOMERICA INC
Form 10-Q
October 15, 2018

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2018

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934

Commission File Number: 0-8765

BIOMERICA, INC.

(Exact name of registrant as specified in its charter)

Edgar Filing: BIOMERICA INC - Form 10-Q

Delaware

95-2645573

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

17571 Von Karman Avenue, Irvine, CA

92614

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number including area code: (949) 645-2111

(Former name, former address and former fiscal year, if changed since last report.)

(TITLE OF EACH CLASS)

(NAME OF EACH EXCHANGE ON WHICH REGISTERED)

Common, par value \$.08

NASDAQ Capital Market

Securities registered pursuant to Section 12(g) of the Act:

(TITLE OF EACH CLASS)

COMMON STOCK, PAR VALUE \$0.08

Indicate by check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (paragraph 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer", "accelerated filer", and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Accelerated Filer

Non-Accelerated Filer

Smaller Reporting Company

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes No

Indicate the number of shares outstanding of each of the registrant's common stock, as of the latest practicable date 9,033,768 shares of common stock, par value \$0.08, as of October 15, 2018.

BIOMERICA, INC.
INDEX

Information Item 1.

Financial Statements:

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Three Months Ended August 31, 2018

1

Condensed Consolidated Balance Sheets (unaudited) August 31, 2018 and (audited) May 31, 2018

2-3

Condensed Consolidated Statements of Cash Flows (unaudited) - Three Months Ended August 31, 2018 and 2017

4

Notes to Condensed Consolidated Financial Statements (unaudited)

5-11

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

12-13

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

13

Item 4.

Controls and Procedures

14

PART II

Other Information

Item 1.

Legal Proceedings

14

Item 1A.

Risk Factors

14

Item 2.

Unregistered Sales of Equity Securities & Use of Proceeds

14

Item 3.

Defaults upon Senior Securities

14

Item 4.

Mine Safety Disclosures

14

Item 5.

Other Information

14

Item 6.

Exhibits

14-15

Signatures

16

PART I - FINANCIAL INFORMATION
SUMMARIZED FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS

BIOMERICA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS(UNAUDITED)

Three Months Ended

		August 31,		
	2018		2017	
Net sales	\$	1,272,870	\$	1,444,483
Cost of sales		(935,647)		(929,912)
Gross profit		337,223		514,571
Operating Expenses:				
Selling, general and administrative		400,228		452,014
Research and development		391,781		288,585
Total operating expenses		792,009		740,599
Loss from operations		(454,786)		(226,028)
Other Income (expense):				
Dividend and interest income		3,093		18,969
Interest expense		(47)		--
Total other income		3,046		18,969
Loss before income tax		(451,740)		(207,059)
Provision for income taxes		--		--
Net loss	\$	(451,740)	\$	(207,059)
Basic net loss per common share	\$	(.05)	\$	(0.02)
Diluted net loss per common share	\$	(.05)	\$	(0.02)
Weighted average number of common and common equivalent shares:				
Basic		8,930,251		8,511,260
Diluted		8,930,251		8,511,260
Net loss	\$	(451,740)	\$	(207,059)
Other comprehensive gain (loss), net of tax:				
Foreign currency translation		(1,326)		(824)
Comprehensive loss	\$	(453,066)	\$	(207,883)

The accompanying notes are an integral part of these statements.

BIOMERICA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

August 31, 2018 (unaudited)	May 31, 2018 (audited)
--	-------------------------------------

Current Assets:

Cash and cash equivalents	583,693
\$	
\$	1,204,903
Accounts receivable, less allowance for doubtful accounts of \$63,392 and \$57,695 as of August 31, 2018 and May 31, 2018, respectively	1,013,687
Inventories	799,940

	2,208,457
	2,178,777
Prepaid expenses and other	
	311,291
	300,409
Total Current Assets	
	4,117,128
	4,484,029
Property and Equipment, net of accumulated depreciation and amortization of \$1,688,423 and \$1,661,128	
	361,935
	351,149

Deferred Tax Assets

10,000